« BACK

Monday, January 25, 2010 :: Imaging Diagnostic Systems Exhibits at
Imaging Diagnostic Systems Exhibits at
Major Middle East Health Conference


Fort Lauderdale, Florida, January 25, 2010—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), a pioneer in laser optical breast imaging is exhibiting CT Laser Mammography (CTLM®) clinical results at the Arab Health 2010 medical conference, January 25-28, 2010, in Dubai, United Arab Emirates (UAE). The company is located at booth RG12.

“Arab Health is an important show for us, as it provides an opportunity to interface with our established clients and present the CTLM technology to potential customers in the UAE and the Middle East,” stated Deborah O’Brien, Senior Vice President.

The Arab Health exhibition and congress is the largest healthcare exhibition in the Middle East, and the second largest in the world. It brings healthcare manufacturers, wholesalers, dealers, and distributors together with some of the most important and influential decision-makers in the Arab world, providing an ideal opportunity for companies to display their latest technology and equipment. With over 2,000 exhibitors from over 50 countries exhibiting and more than 56,000 medical professionals attending in 2009, Arab Health is recognized as a must-attend event in one of the fastest-growing regions in the world.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

The Company is currently undergoing the clinical studies required for the Premarket approval application. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States.

For more information, visit our website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.


Contact:
Deborah O’Brien
954.257.8940